<DOC>
	<DOC>NCT01039701</DOC>
	<brief_summary>The primary purpose of the study is to determine the safety and tolerability of AZD1446 vs Placebo given as an add-on treatment to Donepezil for 4 weeks in patients with mild to moderate Alzheimer's disease.</brief_summary>
	<brief_title>4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>history of progressive worsening of memory and other cognitive functions for at least 12 months treatment with stable dose of donepezil (10 mg) for at least 3 months the patient should have an appropriate caregiver, who is required for all study visits history of allergy/hypersensitivity reactions significant neurological disease or dementia other than Alzheimer's disease myocardial infarction or acute coronary syndrome within the last year</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>mild to moderate Alzheimer's disease</keyword>
	<keyword>To determine the safety and tolerability of AZD1446 vs Placebo given as an add-on treatment to Donepezil in patients with mild to moderate Alzheimer's disease</keyword>
</DOC>